DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Inclacumab
Inclacumab
Inflammation and Cardiometabolic Risk
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
The Two Tontti Tudiul Lui Hi Ha Unit
View Annual Report
(INN) for Biological and Biotechnological Substances
Study on Stabilization of Human Igg4 Antibodies
Roche Group Development Pipeline
Antibody Based Therapy in Coronary Artery Disease and Heart Failure
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
(INN) for Biological and Biotechnological Substances
Strategies to Obtain Diverse and Specific Human Monoclonal
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Top View
Lowering Serum Lipids Via PCSK9-Targeting Drugs: Current Advances and Future Perspectives
2021 Medicines in Development: Health Equity
PDF of Antibody News
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Antibody Based Therapy in Coronary Artery Disease and Heart Failure
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
WO 2018/231759 Al 20 December 2018 (20.12.2018) W !P O PCT
(12) Patent Application Publication (10) Pub. No.: US 2014/0242075A1 Parren Et Al
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
WO 2017/189679 Al 02 November 2017 (02.11.2017) W !P O PCT